Coloplast A/S

OTCPK:CLPB.F Stock Report

Market Cap: US$28.3b

Coloplast Valuation

Is CLPB.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLPB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CLPB.F ($123.01) is trading below our estimate of fair value ($194.77)

Significantly Below Fair Value: CLPB.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLPB.F?

Key metric: As CLPB.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CLPB.F. This is calculated by dividing CLPB.F's market cap by their current earnings.
What is CLPB.F's PE Ratio?
PE Ratio39.7x
EarningsDKK 5.05b
Market CapDKK 200.37b

Price to Earnings Ratio vs Peers

How does CLPB.F's PE Ratio compare to its peers?

The above table shows the PE ratio for CLPB.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.1x
COO Cooper Companies
55.1x23.0%US$19.8b
ALGN Align Technology
38.9x17.5%US$16.7b
SOLV Solventum
16.1x6.0%US$11.7b
MMSI Merit Medical Systems
50.5x14.2%US$5.9b
CLPB.F Coloplast
39.7x12.9%US$200.4b

Price-To-Earnings vs Peers: CLPB.F is good value based on its Price-To-Earnings Ratio (39.7x) compared to the peer average (40.1x).

Price to Earnings Ratio vs Industry

How does CLPB.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.5xn/aUS$12.37m
PAVM PAVmed
0.7x-77.8%US$11.86m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
CLPB.F 39.7xIndustry Avg. 36.2xNo. of Companies11PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CLPB.F is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the US Medical Equipment industry average (37.2x).

Price to Earnings Ratio vs Fair Ratio

What is CLPB.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLPB.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CLPB.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLPB.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$129.60
US$132.47
+2.2%
11.0%US$152.29US$101.52n/a21
Oct ’25US$126.26
US$136.44
+8.1%
11.0%US$158.31US$104.54n/a20
Sep ’25n/a
US$135.79
0%
11.3%US$157.93US$104.30n/a20
Aug ’25US$127.25
US$132.17
+3.9%
11.0%US$154.66US$103.59n/a20
Jul ’25US$118.71
US$128.63
+8.4%
10.5%US$152.27US$101.99n/a20
Jun ’25US$119.53
US$132.45
+10.8%
10.2%US$154.30US$103.35n/a19
May ’25US$119.50
US$131.89
+10.4%
10.9%US$152.45US$100.68n/a19
Apr ’25US$130.91
US$130.41
-0.4%
10.3%US$154.06US$101.74n/a19
Mar ’25US$127.71
US$126.42
-1.0%
10.1%US$145.01US$101.51n/a19
Feb ’25US$117.00
US$120.34
+2.9%
9.8%US$140.54US$92.19n/a19
Jan ’25n/a
US$119.60
0%
10.3%US$140.91US$92.43n/a18
Dec ’24n/a
US$119.39
0%
10.1%US$140.46US$92.13n/a18
Nov ’24US$107.98
US$120.72
+11.8%
9.2%US$139.38US$97.57US$129.6018
Oct ’24US$104.28
US$122.57
+17.5%
9.9%US$141.66US$97.18US$126.2617
Sep ’24US$112.30
US$133.00
+18.4%
10.1%US$156.81US$105.52n/a15
Aug ’24US$122.99
US$139.94
+13.8%
9.9%US$161.20US$108.47US$127.2516
Jul ’24n/a
US$134.20
0%
11.0%US$156.86US$101.15US$118.7116
Jun ’24US$126.88
US$132.29
+4.3%
11.0%US$154.62US$99.71US$119.5316
May ’24US$145.05
US$134.31
-7.4%
10.0%US$153.73US$101.51US$119.5016
Apr ’24US$131.25
US$131.33
+0.06%
9.8%US$152.04US$100.39US$130.9116
Mar ’24US$114.95
US$129.58
+12.7%
10.2%US$149.93US$99.00US$127.7115
Feb ’24n/a
US$133.12
0%
9.7%US$153.32US$101.24US$117.0015
Jan ’24US$115.01
US$130.94
+13.9%
7.7%US$148.92US$113.72n/a15
Dec ’23US$119.37
US$130.10
+9.0%
11.4%US$169.95US$110.80n/a14
Nov ’23US$111.44
US$126.95
+13.9%
12.2%US$163.86US$105.76US$107.9814

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$92.9b

Operates as a health benefits company in the United States.

ELV

US$400.70

7D

-5.8%

1Y

-13.9%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$56.05

7D

0.4%

1Y

-17.9%

Patterson Companies

US$1.7b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$20.90

7D

-0.7%

1Y

-34.7%